

**SH2B1 Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP16002b****Specification**

---

**SH2B1 Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [Q9NRF2](#)**SH2B1 Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 25970**Other Names**

SH2B adapter protein 1, Pro-rich, PH and SH2 domain-containing signaling mediator, PSM, SH2 domain-containing protein 1B, SH2B1, KIAA1299, SH2B

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**SH2B1 Antibody (C-term) Blocking Peptide - Protein Information****Name** SH2B1**Synonyms** KIAA1299, SH2B**Function**

Adapter protein for several members of the tyrosine kinase receptor family. Involved in multiple signaling pathways mediated by Janus kinase (JAK) and receptor tyrosine kinases, including the receptors of insulin (INS), insulin-like growth factor I (IGF1), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), platelet-derived growth factor (PDGF) and fibroblast growth factors (FGFs). In growth hormone (GH) signaling, autophosphorylated ('Tyr-813') JAK2 recruits SH2B1, which in turn is phosphorylated by JAK2 on tyrosine residues. These phosphotyrosines form potential binding sites for other signaling proteins. GH also promotes serine/threonine phosphorylation of SH2B1 and these phosphorylated residues may serve to recruit other proteins to the GHR-JAK2-SH2B1 complexes, such as RAC1. In leptin (LEP) signaling, binds to and potentiates the activation of JAK2 by globally enhancing downstream pathways. In response to leptin, binds simultaneously to both, JAK2 and IRS1 or IRS2, thus mediating formation of a complex of JAK2, SH2B1 and IRS1 or IRS2. Mediates tyrosine phosphorylation of IRS1 and IRS2, resulting in activation of the PI 3- kinase pathway. Acts as a positive regulator of NGF-mediated activation of the Akt/Forkhead pathway; prolongs NGF-induced phosphorylation of AKT1 on 'Ser-473' and AKT1 enzymatic activity.

Enhances the kinase activity of the cytokine receptor-associated tyrosine kinase JAK2 and of other receptor tyrosine kinases, such as FGFR3 and NTRK1. For JAK2, the mechanism seems to involve dimerization of both, SH2B1 and JAK2. Enhances RET phosphorylation and kinase activity. Isoforms seem to be differentially involved in IGF-I and PDGF-induced mitogenesis (By similarity).

**Cellular Location**

Cytoplasm. Membrane. Nucleus. Note=Shuttles between the nucleus and the cytoplasm.

**Tissue Location**

Widely expressed with highest levels in skeletal muscle and ovary.

**SH2B1 Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**SH2B1 Antibody (C-term) Blocking Peptide - Images****SH2B1 Antibody (C-term) Blocking Peptide - Background**

This gene encodes a member of the SH2-domain containing mediators family. The encoded protein mediates activation of various kinases and may function in cytokine and growth factor receptor signaling and cellular transformation. Alternatively spliced transcript variants have been described. [provided by RefSeq].

**SH2B1 Antibody (C-term) Blocking Peptide - References**

Fontaine-Bisson, B., et al. Diabetologia 53(10):2155-2162(2010) Holzapfel, C., et al. Int J Obes (Lond) 34(10):1538-1545(2010) Shi, J., et al. Am. J. Epidemiol. 172(3):244-254(2010) Haupt, A., et al. Obesity (Silver Spring) 18(6):1212-1217(2010) Ng, M.C., et al. J. Clin. Endocrinol. Metab. 95(5):2418-2425(2010)